One-Month Paliperidone Palmitate (PP1) to Three-Month Paliperidone Palmitate (PP3) Switches | ||||||
January 2019 to December 2020 | Number of Unique Patients, by Epoch | |||||
Characteristic | All PP1 to PP3 Switches (n = 2770) | COVID Awareness Period (n = 308) | Primary COVID Escalation Period (n = 420) | COVID Maintenance Period (n = 265) | Second COVID Escalation Period (n = 301) | Pre-COVID Comparator Period (n = 442) |
Gender | ||||||
 Women, n (%) | 822 (29.7) | 86 (27.9) | 119 (28.3) | 80 (30.2) | 87 (28.9) | 149 (33.7) |
 Men, n (%) | 1948 (70.3) | 222 (72.1) | 301 (71.7) | 185 (69.8) | 214 (71.1) | 293 (66.3) |
Age In Years | ||||||
 18–35, n (%) | 1002 (36.2) | 102 (33.1) | 150 (35.7) | 113 (42.6) | 129 (42.9) | 149 (33.7) |
 36–50, n (%) | 922 (33.3) | 104 (33.8) | 133 (31.7) | 81 (30.6) | 92 (30.6) | 158 (35.7) |
 51–64, n (%) | 604 (21.8) | 79 (25.6) | 86 (20.5) | 50 (18.9) | 59 (19.6) | 102 (23.1) |
 65+, n (%) | 242 (8.7) | 23 (7.5) | 51 (12.1) | 21 (7.9) | 21 (7.0) | 33 (7.5) |
Three-Month Paliperidone Palmitate (PP3) to One-Month Paliperidone Palmitate (PP1) Switches | ||||||
January 2019 to December 2020 | Number of Unique Patients, by Epoch | |||||
Characteristic | All PP3 to PP1 Switches (n = 433) | COVID Awareness Period (n = 64) | Primary COVID Escalation Period (n = 48) | COVID Maintenance Period (n = 56) | Second COVID Escalation Period (n = 59) | Pre-COVID Comparator Period (n = 55) |
Gender | ||||||
 Women, n (%) | 133 (30.7) | 22 (34.4) | 18 (37.5) | 15 (26.8) | 18 (30.5) | 18 (32.7) |
 Men, n (%) | 300 (69.3) | 42 (65.6) | 30 (62.5) | 41 (73.2) | 41 (69.5) | 37 (67.3) |
Age In Years | ||||||
 18–35, n (%) | 152 (35.1) | 23 (35.9) | 17 (35.4) | 17 (30.4) | 21 (35.6) | 23 (41.8) |
 36–50, n (%) | 151 (34.9) | 22 (34.4) | 21 (43.8) | 17 (30.4) | 18 (30.5) | 17 (30.9) |
 51+, n (%) | 130 (30.0) | 19 (29.7) | 10 (20.8) | 22 (39.3) | 20 (33.9) | 15 (27.3) |